Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TriSalus Life Sciences, Inc.TLSI · Entity 5872 | Director | August 13, 2024 | August 22, 2024 |
| Werewolf Therapeutics, Inc.HOWL · Entity 7244 | Director | June 11, 2025 | June 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TriSalus Life Sciences, Inc.
Report date August 13, 2024 · Filed August 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 · Expires 2034-08-12 | Direct | 15,000 |
Reported balance
After 2024-08-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-13 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of August 13, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of August 13, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer.
Werewolf Therapeutics, Inc.
Report date June 11, 2025 · Filed June 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 · Expires 2035-06-10 | Direct | 9,000 |
Reported balance
After 2025-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-11 · Grant · Acquired 9,000 · Balance 9,000 F1: Represents stock options that the Reporting Person was entitled to receive pursuant to the non-employee director compensation policy of Werewolf Therapeutics, Inc. (the "Company") in effect at the time of the Reporting Person's appointment to the board of directors of the Company, which were not previously granted due to a clerical error. F2: The option was granted on June 11, 2025. One-third of the total number of shares underlying the option vest on February 19, 2026, and the remaining shares vest thereafter in equal monthly installments until February 19, 2028, subject to continued service by the Reporting Person as a director to the Company through each applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2035-06-11 | Direct | 8,358 |
Reported balance
After 2025-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-12 · Grant · Acquired 8,358 · Balance 8,358 F3: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents stock options that the Reporting Person was entitled to receive pursuant to the non-employee director compensation policy of Werewolf Therapeutics, Inc. (the "Company") in effect at the time of the Reporting Person's appointment to the board of directors of the Company, which were not previously granted due to a clerical error.
F2: The option was granted on June 11, 2025. One-third of the total number of shares underlying the option vest on February 19, 2026, and the remaining shares vest thereafter in equal monthly installments until February 19, 2028, subject to continued service by the Reporting Person as a director to the Company through each applicable vesting date.
F3: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2025 Filed Jun 13, 2025 20:10 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 8,358 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000950170-25-086168 · ownership.xml · derivative · entry 2 Singhal Anil K. · CIK 0001982984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,358 Underlying: Common Stock · 8,358 shares Expires 2035-06-11 F3 · derivative.exercise_date: The option was granted on June 12, 2025. The shares underlying the option vest in full on the earlier of the first anniversary of the grant date and the next annual meeting of stockholders following the grant date, subject to the reporting person's continued service as a director. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:10 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0000950170-25-086168 · ownership.xml · derivative · entry 1 Singhal Anil K. · CIK 0001982984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2035-06-10 F1 · shares: Represents stock options that the Reporting Person was entitled to receive pursuant to the non-employee director compensation policy of Werewolf Therapeutics, Inc. (the "Company") in effect at the time of the Reporting Person's appointment to the board of directors of the Company, which were not previously granted due to a clerical error. F2 · derivative.exercise_date: The option was granted on June 11, 2025. One-third of the total number of shares underlying the option vest on February 19, 2026, and the remaining shares vest thereafter in equal monthly installments until February 19, 2028, subject to continued service by the Reporting Person as a director to the Company through each applicable vesting date. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:57 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0000950170-25-025022 · ownership.xml · derivative · entry 1 Singhal Anil K. · CIK 0001982984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2035-02-18 F1 · derivative.exercise_date: The option was granted on February 19, 2025. The shares underlying the option vest over three years, with one-third of the shares vesting on the first anniversary of the date of grant and the remaining shares vesting in equal monthly installments thereafter. Read SEC document |
| August 13, 2024 Filed Aug 22, 2024 00:37 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantDirector stock option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0001415889-24-021940 · form4-08222024_120848.xml · derivative · entry 1 Singhal Anil K. · CIK 0001982984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2034-08-12 F1 · derivative.exercise_date: The shares subject to the option shall fully vest on the one-year anniversary of the grant date of August 13, 2024, provided that the shares subject to the option will in any case be fully vested on the date of the Issuer's next annual stockholder meeting, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 22:03 UTC | TriSalus Life Sciences, Inc. TLSI · Entity 5872 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-23-045695 · doc4.xml · derivative · entry 1 Singhal Anil K. · CIK 0001982984 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-08-09 F1 · derivative.exercise_date: The shares subject to this stock option vest in three equal annual installments from the vesting commencement date of August 10, 2023, subject to the Reporting Person's continued service with the Issuer on each respective vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.